Esmethadone (REL-1017) Improves Cognitive Function in Patients With Severe Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Post Hoc Analysis From a Phase 3 Randomized Controlled Trial

被引：0

作者：

Guidetti, Clotilde ^{[1
]}

De Martin, Sara ^{[1
]}

Pani, Luca ^{[1
]}

Papakostas, George ^{[1
]}

Pappagallo, Marco ^{[1
]}

Serra, Giulia ^{[1
]}

Apicella, Massimo ^{[1
]}

Manfredi, Paolo ^{[1
]}

Fava, Maurizio ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA USA

来源：

NEUROPSYCHOPHARMACOLOGY | 2024年 / 49卷

关键词：

NMDA Antagonists; Subjective Cognitive Impairment; Major Depressive Disorder (MDD);

D O I：

暂无

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

P169

引用

页码：160 / 161

页数：2

共 26 条

[21] EFFECT OF PRIOR ESOPHAGEAL DILATION ON HISTOLOGIC, SYMPTOM AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: POST HOC ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION
Hirano, Ikuo
Collins, Margaret H.
Katzka, David A.
Mukkada, Vincent A.
Falk, Gary W.
Terreri, Brian
Boules, Mena
Zhang, Wenwen
Desai, Nirav K.
Dellon, Evan S.
GASTROENTEROLOGY, 2022, 162 (07) : S530 - S530
[22] Improvement in Symptoms of Depression and Anxiety With Zuranolone Treatment in Patients With Major Depressive Disorder: HAM-A Analysis From the Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Waterfall Study
Kanes, Stephen J.
Clayton, Anita
Jung, JungAh
Brown, Colville
Lasser, Robert
Doherty, James
NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 187 - 188
[23] EFFICACY AND SAFETY OF ORAL DIFELIKEFALIN IN STAGE 3-5 CHRONIC KIDNEY DISEASE PATIENTS WITH MODERATE-TO-SEVERE PRURITUS: A RESPONSE ANALYSIS FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL
Yosipovitch, Gil
Awad, Ahmed
Spencer, Robert
Munera, Catherine
Menzaghi, Frederique
AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 75 (05) : 820 - 820
[24] 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies
Rosen, Noah
Pearlman, Eric
Ruff, Dustin
Day, Kathleen
Nagy, Abraham Jim
HEADACHE, 2018, 58 (09): : 1347 - 1357
[25] Tenapanor's Sustained Response in Patients With Constipation Predominant Irritable Bowel Syndrome: Post-hoc Analysis From a 12-Week, Double-Blind, Placebo-Controlled, Randomized Phase 2b Trial
Chey, William D.
Lembo, Anthony J.
Rosenbaum, David P.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S756 - S756
[26] 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies (vol 58, pg 1347, 2018)
Rosen, N.
Pearlman, E.
Ruff, D.
Nagy, Jim A.
HEADACHE, 2019, 59 (08): : 1428 - 1428

← 1 2 3 →